Skip to main content
Toggle navigation
Login
Search
Home
Schedule at a Glance
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back
Favorite
Tweet
Print
Meng Qian, PhD
Daiichi Sankyo, Inc.
Poster(s):
(P 44) TUMOR RESPONSE AND REGROWTH IN RELATION TO CLINICAL EVENTS AMONG PEXIDARTINIB-TREATED SUBJECTS IN THE PHASE 3 ENLIVEN TRIAL
(P 400) A LONG-TERM PHASE 4 STUDY TO EVALUATE THE RISK OF HEPATOTOXICITY ASSOCIATED WITH PEXIDARTINIB TREATMENT
